Drug Profile
Research programme: branched chain fatty acid-based therapeutics - Viswa
Alternative Names: 12-MTA; Eye disorders therapeutics - ViswaLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Viswa Biotechnology
- Developer Queen Elizabeth Hospital
- Class
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Eye-disorders in Australia
- 13 Dec 2006 Preclinical trials in Eye disorders in Australia (unspecified route)